FDA adds ovarian cancer to Avastin's label

FDA approved an sBLA from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) for Avastin bevacizumab to treat recurrent platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin.The humanized mAb against VEGF was under Priority Review for the indication.

Avastin is approved in the U.S. to treat metastatic colorectal cancer (mCRC), unresectable or metastatic non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and recurrent glioblastoma multiforme (rGBM). The European Commission approved its use to treat recurrent platinum-resistant ovarian cancer in August. ...